Azurity Pharma acquires Arbor Pharma
The acquisition creates a leading company offering innovative, high-value products to meet the unique needs of patients with underserved conditions. With this acquisition, Arbor is now a wholly-owned subsidiary of Azurity. The two companies will begin to integrate their operations over the coming months and will operate as Azurity post-integration.
Related news and insights
Recordati announces the signing of a share purchase agreement to acquire EUSA Pharma (UK) Ltd, a global specialty pharmaceutical company with headquarters in the United Kingdom, focused on rare and niche oncology diseases and controlled by funds managed by EW Healthcare Partners.
Sanofi announced that it entered into an agreement to acquire Origimm Biotechnology GmbH, an Austrian privately owned biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease, such as acne.